Ann: Positive EMA Meeting For Phase 3 Disc Repair Program, page-5

The pilot program is only to  facilitate early dialogue between

(a) the European Medicines Agency (EMA),
(b) European Health Technology Assessment (HTA) reimbursement bodies and
(c) selected companies with late stage clinical development programs.

So MSB was one of only 7 candidates chosen for the Shaping Early European Dialogues (SEED) program?

pfft!?

It only means fast tracking (again!) for reimbursement (which means money! no point having products that are not reimbursed by government programs or insurers).

Income, and sooner? These practical timing and income implications are clear.

You have to ask yourself why anyone would regard this as not substantial news or irrelevant?

You'd have to say there are vested interests in being relentlessly negative, and deliberately obtuse, surely?

(jokers aside)